

Monoclonal Anti-Polatuzumab Antibody, Mouse IgG1 (2H7)

Catalog # POB-MY2484



Source

Monoclonal Anti-Polatuzumab Antibody, Mouse IgG1 (2H7) is a recombinant mouse monoclonal antibody expressed in HEK293 cells.

Antibody Type

Recombinant Monoclonal

Clone

2H7

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Specificity

Specifically recognizes Human Polatuzumab; This antibody is a neutralizing antibody.

Purification

Protein A purified / Protein G purified.

Aggregation

Less than 5%, as determined by SEC-MALS.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 µm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


Notices

Product Specific Notices: For research use only.

ACRO Quality Management System

- [QMS\(ISO, GMP\)](#).
- [Quality Advantages](#)
- [Quality Control Process](#)

Bioactivity-ELISA



Immobilized Monoclonal Anti-Polatuzumab Antibody, Mouse IgG1 (2H7) (Cat. No. POB-MY2484) at 5 µg/mL, add Polatuzumab and then add Biotinylated Monoclonal Anti-Polatuzumab Antibody, Mouse IgG1 (4A11) (Cat. No. POB-BLMY2485) at 2 µg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

Background

Polatuzumab is a genetically engineered humanized monoclonal antibody directed against the CD79b antigen (B-cell receptor complex-associated protein beta chain) found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine complementarity-determining region (CDR) sequences grafted into human framework regions of the variable domains and human constant region sequences. Polatuzumab is composed of two heavy chains of 452 amino acids and two light chains of 214 amino acids.

Discounts, Gifts,
and more!



Acro



www.acrobiosystems.com